Lessons Learned in Time-Is Neurodegeneration Still Something Unpredictable?
作者信息
Hu William T
机构信息
Department of Neurology, Rutgers-Robert Wood Johnson Medical School, 125 Paterson Street, Suite 6200, New Brunswick, NJ, 08901, USA.
Institute for Health, Health Care Policy, and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, 08901, USA.
出版信息
Neurotherapeutics. 2023 Jul;20(4):911-913. doi: 10.1007/s13311-023-01412-1. Epub 2023 Aug 11.
Abstract
摘要
相似文献
1
Lessons Learned in Time-Is Neurodegeneration Still Something Unpredictable?及时吸取的教训——神经退行性变仍然不可预测吗？
Neurotherapeutics. 2023 Jul;20(4):911-913. doi: 10.1007/s13311-023-01412-1. Epub 2023 Aug 11.
2
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.PTI-125 降低阿尔茨海默病患者的生物标志物。
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
3
Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer's Disease Proteinopathy.类似于阿尔茨海默病蛋白病变的海马体缺血后神经变性。
Int J Mol Sci. 2021 Dec 28;23(1):306. doi: 10.3390/ijms23010306.
4
Alzheimer's disease/dementia-associated brain pathology in aging DPP6-KO mice.衰老 DPP6-KO 小鼠的阿尔茨海默病/痴呆相关脑病理学。
Neurobiol Dis. 2022 Nov;174:105887. doi: 10.1016/j.nbd.2022.105887. Epub 2022 Oct 6.
5
Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.与颞叶癫痫认知障碍相关的阿尔茨海默样淀粉样蛋白和tau 改变。
Brain. 2020 Jan 1;143(1):191-209. doi: 10.1093/brain/awz381.
6
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.阿尔茨海默病死后视网膜中的淀粉样β和磷酸化tau。
Acta Neuropathol Commun. 2018 Dec 28;6(1):147. doi: 10.1186/s40478-018-0650-x.
7
Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.血浆 tau/淀粉样蛋白-β1-42 比值可预测阿尔茨海默病患者的脑 tau 沉积和神经退行性变。
Brain. 2019 Mar 1;142(3):771-786. doi: 10.1093/brain/awy347.
8
Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.阿尔茨海默病的起源：调和关于淀粉样蛋白-β和 tau 参与的时间顺序的脑脊液生物标志物和神经病理学数据。
Curr Opin Neurol. 2012 Dec;25(6):715-20. doi: 10.1097/WCO.0b013e32835a30f4.
9
Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction.帕金森病和阿尔茨海默病的神经病理学和生物标志物研究：从蛋白聚集到突触功能障碍。
J Parkinsons Dis. 2021;11(1):107-121. doi: 10.3233/JPD-202323.
10
Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer's Disease.淀粉样蛋白和 Tau 蛋白参与与阿尔茨海默病相似的自然状态下缺血性海马神经退行性变。
Int J Mol Sci. 2021 Feb 28;22(5):2460. doi: 10.3390/ijms22052460.
本文引用的文献
1
The Role of Clinical Assessment in the Era of Biomarkers.临床评估在生物标志物时代的作用。
Neurotherapeutics. 2023 Jul;20(4):1001-1018. doi: 10.1007/s13311-023-01410-3. Epub 2023 Aug 18.
2
Intersectionality in Alzheimer's Disease: The Role of Female Sex and Black American Race in the Development and Prevalence of Alzheimer's Disease.阿尔茨海默病中的交叉性：女性性别和非裔美国人种族在阿尔茨海默病的发展和流行中的作用。
Neurotherapeutics. 2023 Jul;20(4):1019-1036. doi: 10.1007/s13311-023-01408-x. Epub 2023 Jul 25.
3
Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.抗淀粉样蛋白免疫疗法治疗阿尔茨海默病：2023 年临床更新。
Neurotherapeutics. 2023 Jul;20(4):914-931. doi: 10.1007/s13311-023-01405-0. Epub 2023 Jul 25.
4
A Real-Time Neurophysiologic Stress Test for the Aging Brain: Novel Perioperative and ICU Applications of EEG in Older Surgical Patients.实时神经生理应激测试在老年大脑中的应用：老年手术患者 EEG 在围手术期和 ICU 的新应用。
Neurotherapeutics. 2023 Jul;20(4):975-1000. doi: 10.1007/s13311-023-01401-4. Epub 2023 Jul 12.
5
Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias.绘制阿尔茨海默病和相关痴呆症中 CSF 生物标志物的下一个路线图。
Neurotherapeutics. 2023 Jul;20(4):955-974. doi: 10.1007/s13311-023-01370-8. Epub 2023 Jun 28.
6
Fluid and Biopsy Based Biomarkers in Parkinson's Disease.基于液体和活检的帕金森病生物标志物。
Neurotherapeutics. 2023 Jul;20(4):932-954. doi: 10.1007/s13311-023-01379-z. Epub 2023 May 3.
7
Lecanemab in Early Alzheimer's Disease. Reply.用于早期阿尔茨海默病的lecanemab。回复。
N Engl J Med. 2023 Apr 27;388(17):1631-1632. doi: 10.1056/NEJMc2301380.
8
Trial of Prasinezumab in Early-Stage Parkinson's Disease.普拉克索尼单抗治疗早期帕金森病的试验。
N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867.
9
Trial of Cinpanemab in Early Parkinson's Disease.西尼潘单抗治疗早期帕金森病的临床试验。
N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.
10
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.抗 tau 单克隆抗体 gosuranemab 在进行性核上性麻痹中的安全性和疗效：一项 2 期、随机、安慰剂对照试验。
Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12.
Zotero 插件